Champions Oncology, Inc. (NASDAQ: CSBR) signs a strategic partnership with TransCure bioServices SAS
This newly signed partnership combines Champions’ patient sourced cancer models with TransCure’s full human immune system mouse models for more predictive preclinical cancer drug development throughout Europe. Champions and TransCure’s European customers are offered access to a centralized and unique set of interactions with the respective companies allowing to perform PDX studies and the pharmacology work locally, reducing the intercontinental logistics involved with performing the work only in the US.